SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 218 filers reported holding SAGE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $249,579 | -46.1% | 12,129 | +23.3% | 0.00% | -100.0% |
| Q2 2023 | $462,640 | -17.5% | 9,840 | -26.3% | 0.00% | 0.0% |
| Q1 2023 | $560,543 | +6.2% | 13,360 | -3.3% | 0.00% | 0.0% |
| Q4 2022 | $528,000 | -1.5% | 13,823 | +1.1% | 0.00% | 0.0% |
| Q3 2022 | $536,000 | +19.9% | 13,673 | -1.0% | 0.00% | 0.0% |
| Q2 2022 | $447,000 | +18.3% | 13,814 | +21.1% | 0.00% | 0.0% |
| Q1 2022 | $378,000 | +27.7% | 11,406 | +63.6% | 0.00% | 0.0% |
| Q4 2021 | $296,000 | +166.7% | 6,974 | +175.7% | 0.00% | – |
| Q3 2021 | $111,000 | -78.9% | 2,530 | -72.5% | 0.00% | -100.0% |
| Q2 2021 | $527,000 | +621.9% | 9,211 | +852.5% | 0.00% | – |
| Q1 2021 | $73,000 | -26.3% | 967 | -15.2% | 0.00% | – |
| Q4 2020 | $99,000 | +219.4% | 1,141 | +121.1% | 0.00% | – |
| Q3 2020 | $31,000 | -3.1% | 516 | -35.3% | 0.00% | – |
| Q2 2020 | $32,000 | +28.0% | 798 | -10.6% | 0.00% | – |
| Q1 2020 | $25,000 | – | 893 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |